Mon-Fri 9am-6pm PST
+1 (800) 686-5898
support@longevitybased.com
Mon-Fri: 9am-6pm PST
When it comes to diet, many expect a specific branded approach, such as low-carb, Mediterranean, or a strict elimination plan.
A more useful answer is simpler. The diet that reliably improves insulin resistance is the one that creates sustained weight loss and is easy enough to maintain long term. Newer research comparing different diet patterns supports that idea.
Insulin is a hormone that helps move glucose from the bloodstream into cells where it can be used for energy.
After eating, blood glucose rises. The pancreas releases insulin, and glucose is cleared back toward normal levels.
In insulin resistance, cells respond poorly to insulin. The pancreas compensates by producing more insulin, but blood glucose still tends to stay higher than it should. Over time this can progress to type 2 diabetes.
Insulin resistance is not just a lab value. It is linked to downstream problems including:
Damage to blood vessels and organs from chronically elevated glucose
Higher risk of cardiovascular disease
Higher risk of infections
Worsening inflammation
Progression to type 2 diabetes
Insulin resistance is tightly linked to excess body fat, especially in people with obesity. A large share of people with obesity develop insulin resistance over time.
Weight loss is one of the most reliable ways to improve insulin sensitivity.
A meta-analysis in overweight people with type 2 diabetes found a dose-response relationship:
More weight loss was associated with larger improvements in blood sugar control
The analysis reported an approximate rule of thumb:
For each 1 kg of weight lost, HbA1c dropped by about 0.1 percentage points
HbA1c reflects average blood glucose over roughly three months. A 1 percent drop can be clinically meaningful. A 10 kg weight loss could, in some cases, shift someone from the diabetic range toward normal glycemic levels.
Not all fat has the same metabolic impact.
Subcutaneous fat is stored under the skin. Visceral fat is stored deeper in the abdomen around organs such as the liver and intestines.
Visceral fat is strongly linked to insulin resistance, while subcutaneous fat appears less directly harmful in this context. Weight loss tends to reduce visceral fat and improve insulin sensitivity.
This leads to a common question: does the best diet specifically target visceral fat
A 2022 trial tested whether different carbohydrate patterns changed visceral fat loss when calories were kept similar.
Participants were placed into one of three diets:
Whole-grain flour-based carbohydrates such as bread and pasta
Minimally processed carbohydrates such as fruit, potatoes, and rice
A low-carb diet higher in fat
All groups were instructed to minimize added sugars and sugary drinks. Visceral fat was measured at baseline, six months, and twelve months.
The result was not what many people expect.
All three groups lost substantial visceral fat. The low-carb group showed meaningful reductions, but the other groups also lost a lot, and differences between groups were not statistically significant.
There were trends that appeared to favor low-carb and minimally processed carbs, but the study was not large enough to confidently separate real effects from normal variation.
A key limitation was dropout.
The trial started with 193 participants and ended with only 57 at twelve months. High dropout can make results look better than they are if the people who are not losing weight are the ones most likely to leave.
This does not invalidate the findings, but it means we should interpret them cautiously.
The diets differed in carbohydrate content and food choices, but they shared one critical feature.
They created a mild calorie deficit.
Across weight loss research, energy deficit repeatedly emerges as the dominant driver of weight loss, regardless of whether the diet is low-carb, low-fat, or Mediterranean-style.
This is also why most diets look similar at six months and then diverge based on adherence at twelve months.
Most structured diets produce moderate weight loss at about six months.
By twelve months, much of that weight loss often returns. Over longer time horizons, the majority of lost weight is commonly regained.
This is not a moral failure. It reflects how difficult it is to maintain highly restrictive eating patterns in real life.
That is why the best diet is usually the one a person can stick with for years, not weeks.
Rather than obsessing over the perfect diet label, it is often more productive to focus on principles that improve satiety and reduce calorie intake without excessive restriction.
For people without inflammatory bowel disease or significant IBS symptoms, increasing fiber can improve fullness and reduce calorie intake.
In one study, increasing fiber by 14 grams per day was associated with:
About a 10 percent reduction in calories consumed
Around 1.9 kg weight loss over follow-up
Fiber is also associated with broader health benefits, including improved digestive function and more favorable cardiovascular risk markers.
Protein increases satiety and can make appetite control easier during weight loss.
It also helps preserve lean mass. In a calorie deficit, some lean mass loss is common. Higher protein intake reduces that risk.
A practical target often used in clinic is:
About 1.2 g of protein per kg of ideal body weight per day
This is not a universal requirement, but it is a reasonable starting point for many adults trying to lose weight while preserving muscle.
This is one of the simplest ways to lower calorie intake without tracking everything.
Ultra-processed foods are easy to overeat. Sugary drinks are particularly problematic because they add calories without improving satiety.
Exercise improves insulin sensitivity even without dramatic weight loss. It also helps preserve muscle during weight loss and improves cardiovascular fitness, which matters independently of glucose control.
Some people do the right things with diet and exercise and still struggle to reach weight loss targets or improve glycemic control.
In those cases, GLP-1 medications can be appropriate. Using medication is not a failure. These drugs can be highly effective for improving weight and blood sugar outcomes.
Newer drugs that combine GLP-1 with GIP signaling, such as tirzepatide, can produce larger effects on weight loss and glycemic control than GLP-1 alone in many patients.
Medication decisions should be individualized and monitored, but they are increasingly part of evidence-based diabetes care.
Weight loss is one of the strongest levers for improving insulin resistance
Visceral fat is especially linked to insulin resistance, and weight loss reduces visceral fat
In controlled trials, different diet patterns can reduce visceral fat similarly when calories are similar
The most important factor for weight loss is sustained calorie deficit
Long-term adherence matters more than diet branding
Fiber and lean protein can make calorie deficit easier to maintain
Exercise improves insulin sensitivity and supports long-term health
Medications can be appropriate when lifestyle efforts are not enough
The best diet for insulin resistance is usually not the most extreme or fashionable one. It is the one you can sustain while maintaining a calorie deficit long enough to lose meaningful weight, particularly visceral fat.
If you focus on a few high-leverage principles, higher fiber when tolerated, adequate protein, less ultra-processed food, and consistent movement, you can improve insulin sensitivity without needing a complicated dietary identity. Medications can be added when needed, but the foundation remains a diet that works for your life, not just on paper.
Research sources:
https://www.atherosclerosis-journal.com/article/S0021-9150(24)00167-9/abstract
https://www.uptodate.com/contents/insulin-resistance-definition-and-clinical-spectrum
https://pubmed.ncbi.nlm.nih.gov/28417575/
https://diabetes.org/about-diabetes/a1c
https://my.clevelandclinic.org/health/diseases/24147-visceral-fat
https://pmc.ncbi.nlm.nih.gov/articles/PMC4038351/
https://www.clinicalnutritionjournal.com/article/S0261-5614(22)00322-3/fulltext
https://pmc.ncbi.nlm.nih.gov/articles/PMC7190064/
https://pmc.ncbi.nlm.nih.gov/articles/PMC8017325/
https://pmc.ncbi.nlm.nih.gov/articles/PMC5764193/
https://pubmed.ncbi.nlm.nih.gov/30638909/
https://pmc.ncbi.nlm.nih.gov/articles/PMC8017325/
https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
https://pmc.ncbi.nlm.nih.gov/articles/PMC4608087/
https://www.nejm.org/doi/full/10.1056/NEJMoa2107519